Tutorials
Cogent Biosciences Inc logo

Cogent Biosciences Inc

$ 14.13 +0.68 (+5.06%) 08:08 PM EST
P/E:
At Loss
P/B:
3.74
Market Cap:
$ 929.16M
Enterprise V:
$ 703.07M
Volume:
861.84K
Avg Vol (2M):
1.82M
Volume:
861.84K
Market Cap $:
929.16M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.82M
Enterprise Value $:
703.07M
PB Ratio:
3.74
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Cogent Biosciences Inc
NAICS : 325412 SIC : 2834
200 Cambridge Park Drive, Suite 2500, Cambridge, MA, USA, 02140
Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Name Current Vs Industry Vs History
Cash-To-Debt 11.6
Equity-to-Asset 0.87
Debt-to-Equity 0.09
Debt-to-EBITDA -0.25
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -2.37
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 81.91
9-Day RSI 76.85
14-Day RSI 73.35
6-1 Month Momentum % 65.32
12-1 Month Momentum % 36.77

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 11.96
Quick Ratio 11.96
Cash Ratio 11.77

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -80
Name Current Vs Industry Vs History
ROE % -48.41
ROA % -43.86
ROIC % -468.86
ROC (Joel Greenblatt) % -1155.87
ROCE % -48.76

Financials (Next Earnings Date:2022-11-10 Est.)

COGT's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:COGT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -2.439
Beta 2.29
Volatility % 116.8
14-Day RSI 73.35
14-Day ATR ($) 0.911824
20-Day SMA ($) 11.728
12-1 Month Momentum % 36.77
52-Week Range ($) 3.79 - 14.58
Shares Outstanding (Mil) 65.76

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cogent Biosciences Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More